Protective effect of phycocyanin on liver injury after partial hepatectomy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this randomized, placebo-controlled trial, adults undergoing planned partial liver resection will receive either phycocyanin or a matched placebo for three weeks before and three weeks after surgery to see if it reduces liver injury and supports liver regrowth. The safety of phycocyanin in this surgical setting will also be evaluated by monitoring side effects and adverse events. Participants will provide blood and stool samples and will continue with standard perioperative care. Neither participants nor investigators will know which treatment is being administered during the study. About 30 participants are planned to enroll at a single center in Hangzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of intrahepatic cholangiocarcinoma
* Child-Pugh class A liver function
* Planned neoadjuvant treatment with gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor
* Planned anatomical hemihepatectomy with an expected future liver remnant greater than 40%
* Age 18 to 75 years
* Willing and able to participate and provide written informed consent
* No acute illness or significant worsening of symptoms within 4 weeks before enrollment

Exclusion Criteria:

* Serious coexisting medical conditions
* Known allergy to phycocyanin
* Other malignant tumors
* Previous liver resection
* History of severe psychiatric illness that may affect treatment adherence

Where it's running

• The Second Affiliated Hospital of Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xiaopeng Cai
• Email: cxpeng@zju.edu.cn
• Phone: +86 18768161626

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perioperative therapy with Retlirafusp alfa, Famitinib, and HAIC-GEMOX for locally advanced intrahepatic cholangiocarcinoma

  This trial tests whether a perioperative treatment combo (Retlirafusp alfa, famitinib, and HAIC-GEMOX) can help shrink or control locally advanced intrahepatic cholangiocarcinoma before surgery and support additional therapy afterward in adults.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07847710

• Adjuvant therapy after liver surgery for high-risk intrahepatic cholangiocarcinoma

  This real-world study tests three adjuvant treatment approaches after curative liver surgery in people with high-risk intrahepatic cholangiocarcinoma to see which option performs best.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07640048

• Scout-dose check using resin microspheres before yttrium-90 treatment for liver tumors

  This test tries a small 'scout' dose of the same resin microspheres used in yttrium-90 treatment to better measure lung shunt in adults with liver cancer or liver metastases.

  Recruiting Seoul National University Hospital · Seoul · NCT07476651

• 68Ga‑FAPI PET/CT imaging for biliary tract cancers

  We will test whether 68Ga‑FAPI PET/CT scans can find and stage gallbladder cancer and intrahepatic cholangiocarcinoma more accurately than standard FDG PET/CT in adults with suspected or known disease.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT07337850

• Blood test using cfDNA methylation to screen for biliary tract cancers

  This study tests whether a blood test that reads cfDNA methylation can detect biliary tract cancers early in adults with or suspected of having these cancers.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07176962

• Preoperative Lymph Node Assessment in Cholangiocarcinoma using Endoscopic Ultrasound

  This study tests how well preoperative endoscopic ultrasound (EUS) finds lymph node metastases in adults with presumed resectable or certain unresectable cholangiocarcinomas to see if surgery should proceed.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland and 5 other locations · NCT07161869

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.